Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4B | O94953 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858105 | 0.90 | NAMPT (0.44) | NAMPTSIGMAR1GAATMEM97 | |
| SCHEMBL1853253 | 0.90 | NAMPT (0.44) | NAMPTSIGMAR1GAATMEM97 | |
| SCHEMBL1854548 | 0.90 | GAA (0.45) | NPC1RAB9AALDH1A1HPGDMMP12 | |
| SCHEMBL1855554 | 0.87 | EPHX2 (0.45) | MMP12MMP13 | |
| SCHEMBL1855533 | 0.86 | GPR139 (0.43) | SIGMAR1ALDH1A1MMP12MMP13MEN1 | |
| SCHEMBL1851611 | 0.86 | GAA (0.43) | NPC1RAB9ASIGMAR1MMP12MMP13 | |
| SCHEMBL5047546 | 0.85 | NPC1 (0.50) | F10NPC1RAB9AKDM4BNAMPT | |
| SCHEMBL1854024 | 0.81 | NAAA (0.49) | NAMPTSIGMAR1GAATMEM97 | |
| SCHEMBL1855755 | 0.81 | TMEM97 (0.51) | F10NPC1RAB9AKDM4BNAMPT | |
| SCHEMBL6022596 | 0.80 | F10 (0.49) | F10NPC1RAB9AKDM4BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | claimed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | claimed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | TNNI3, TNNT2, ADM2 | F10 1295/4885NPC1 2286/4885RAB9A 2333/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | F10 4164/4885NPC1 2939/4885RAB9A 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.